EFGARTIGIMOD ALFA

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 13:11:21 GMT 2023` Edited by `admin` on `Sat Dec 16 13:11:21 GMT 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	961YV2O515
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

EFGARTIGIMOD ALFA

Official Name

English

MUTATED HUMAN IMMUNOGLOBULIN G1 FC FRAGMENT ANTI-(HOMO SAPIENS IGG RECEPTOR FCRN LARGE SUBUNIT P51 (NEONATAL FC RECEPTORFCRN))(37-TYR(M>Y(32),39-THR(S>T(34),41-GLU(T>E(36),218-LYS(H>K(213)),219-PHE(N>F(214))(FC FRAGMENT OF HUMAN IMMUNOGLOBULIN HEAVY CONS

Common Name

English

efgartigimod alfa [INN]

Common Name

English

EFGARTIGIMOD

Common Name

English

Efgartigimod alfa [WHO-DD]

Common Name

English

IMMUNOGLOBULIN G1, ANTI-(FCRN RECEPTOR) (HUMAN MONOCLONAL ARGX-113 FC FRAGMENT)

Common Name

English

EFGARTIGIMOD ALFA [USAN]

Common Name

English

EFGARTIGIMOD ALFA [JAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

633218

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

EU-Orphan Drug

EU/3/21/2555

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

EU-Orphan Drug

EU/3/18/1992

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

FDA ORPHAN DRUG

825421

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

FDA ORPHAN DRUG

527316

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

Code System Code Type Description

WIKIPEDIA

Efgartigimod alfa

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

DAILYMED

961YV2O515

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

NCI_THESAURUS

C171817

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

RXCUI

2587717

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

FDA UNII

961YV2O515

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

USAN

HI-153

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

DRUG BANK

DB15270

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

CAS

1821402-21-4

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

INN

10455

Created by admin on Sat Dec 16 13:11:21 GMT 2023 , Edited by admin on Sat Dec 16 13:11:21 GMT 2023

PRIMARY

From	To
1_41	1_101
1_147	1_205
2_41	2_101
2_147	2_205
1_6	2_6
1_9	2_9

Glycosylation Link Type	Site
N	1_77
N	2_77

Related Record Type Details

Efgartigimod alfa-QVFC

SUB_CONCEPT->SUBSTANCE

Amount:

Efgartigimod alfa-FCAB

SUB_CONCEPT->SUBSTANCE

Amount:


					TW3XAW0RCY

NEONATAL FC RECEPTOR

TARGET -> INHIBITOR

Comments:

An antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (IgG) back into the blood.[2] The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis.

Amount:

Related Record Type Details


					961YV2O515

EFGARTIGIMOD ALFA

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL